{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:36:29Z","timestamp":1792125389842,"version":"4.4.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":3474,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1111\/jth.12219","type":"journal-article","created":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:19:35Z","timestamp":1372637975000},"page":"316-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"S1","title":["Antiplatelet therapy: new pharmacological agents and changing paradigms"],"prefix":"10.1016","volume":"11","author":[{"given":"D.","family":"Capodanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12219_bb0010","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"Angiolillo","year":"2010","journal-title":"Circ J"},{"key":"10.1111\/jth.12219_bb0020","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIR.0b013e31820f2f3e","volume":"123","author":"Wright","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0025","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American college of cardiology foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0030","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.12219_bb0035","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.12219_bb0040","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0045","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST\u2010segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0050","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the Reduction of Events during Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/jth.12219_bb0055","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo\u2010controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/jth.12219_bb0060","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST\u2010segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1160\/TH09-03-0185","article-title":"Clopidogrel response variability: current status and future directions","volume":"102","author":"Ferreiro","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12219_bb0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0300-8932(10)70010-5","article-title":"Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions","volume":"63","author":"Angiolillo","year":"2010","journal-title":"Rev Esp Cardiol"},{"key":"10.1111\/jth.12219_bb0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jcin.2011.03.001","article-title":"Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations","volume":"4","author":"Angiolillo","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1111\/jth.12219_bb0080","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0085","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on\u2010treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0090","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0095","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double\u2010dose versus standard\u2010dose clopidogrel and high\u2010dose versus low\u2010dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT\u2010OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/jth.12219_bb0100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard\u2010 vs high\u2010dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1111\/jth.12219_bb0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/CIRCINTERVENTIONS.111.966176","article-title":"New directions in antiplatelet therapy","volume":"5","author":"Ferreiro","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1111\/jth.12219_bb0110","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","article-title":"Aspirin as an antiplatelet drug","volume":"330","author":"Patrono","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0115","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2165\/11640880-000000000-00000","article-title":"The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day","volume":"72","author":"Angiolillo","year":"2012","journal-title":"Drugs"},{"key":"10.1111\/jth.12219_bb0120","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.jacc.2007.11.080","article-title":"The role of aspirin in cardiovascular prevention: implications of aspirin resistance","volume":"51","author":"Gasparyan","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/FJC.0b013e3181d8bc8a","article-title":"The thromboxane\/endoperoxide receptor (TP): the common villain","volume":"55","author":"F\u00e9l\u00e9tou","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/jth.12219_bb0130","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1160\/TH10-03-0195","article-title":"Prostanoid and TP\u2010receptors in atherothrombosis: is there a role for their antagonism?","volume":"104","author":"Giannarelli","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12219_bb0135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2174\/092986712803414240","article-title":"New perspectives in antiplatelet therapy","volume":"19","author":"Tello\u2010Montoliu","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1111\/jth.12219_bb0140","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1538-7836.2005.01468.x","article-title":"The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies","volume":"3","author":"Gaussem","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12219_bb0145","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","article-title":"Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double\u2010blind, parallel\u2010group trial","volume":"377","author":"Bousser","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/jth.12219_bb0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1476-5381.1994.tb13033.x","article-title":"Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist","volume":"1121","author":"Modesti","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jth.12219_bb0155","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1161\/01.CIR.87.5.1563","article-title":"Effect of picotamide on the clinical progression of peripheral vascular disease. A double\u2010blind placebo\u2010controlled study","volume":"875","author":"Balsano","year":"1993","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0160","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1046\/j.1365-2125.1996.00503.x","article-title":"Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study","volume":"426","author":"Milani","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jth.12219_bb0165","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ehj.2004.07.013","article-title":"Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2\u2010year mortality in diabetics with peripheral arterial disease: the DAVID study","volume":"25","author":"Neri Serneri","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.12219_bb0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0167-5273(95)02476-D","article-title":"Ridogrel as an adjunct to thrombolysis in acute myocardial infarction","volume":"52","author":"van der Wieken","year":"1995","journal-title":"Int J Cardiol"},{"key":"10.1111\/jth.12219_bb0175","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11239-012-0795-6","article-title":"Pharmacodynamic effects of EV\u2010077: results of an in vitro pilot investigation in healthy volunteers","volume":"34","author":"Tello\u2010Montoliu","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.12219_bb0180","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.thromres.2012.08.309","article-title":"EV\u2010077 in vitro inhibits platelet aggregation in type\u20102 diabetics on aspirin","volume":"130","author":"Sakariassen","year":"2012","journal-title":"Thromb Res"},{"issue":"Suppl","key":"10.1111\/jth.12219_bb0185","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ahj.2008.06.004","article-title":"Pharmacology of emerging novel platelet inhibitors","volume":"2","author":"Angiolillo","year":"2008","journal-title":"Am Heart J"},{"key":"10.1111\/jth.12219_bb0190","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0195","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0200","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(08)60422-5","volume":"371","author":"Wiviott","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/jth.12219_bb0205","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1161\/CIRCULATIONAHA.111.041160","volume":"125","author":"Bonaca","year":"2012","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0210","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","volume":"51","author":"Antman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0215","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0220","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST\u2010elevation myocardial infarction (TRITON\u2010TIMI 38): double\u2010blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/jth.12219_bb0225","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1093\/eurheartj\/ehn362","article-title":"Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON\u2010TIMI 38 trial","volume":"29","author":"Murphy","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.12219_bb0230","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.amjcard.2011.05.020","article-title":"Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON\u2010TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies","volume":"108","author":"Wiviott","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1111\/jth.12219_bb0235","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0240","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug\u2010eluting stents: results of the TRIGGER\u2010PCI Study","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0245","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/0091270010367429","article-title":"Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent","volume":"51","author":"Small","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jth.12219_bb0250","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.jacc.2012.08.964","article-title":"Reduction in platelet reactivity with prasugrel 5\u00a0mg in low\u2010body\u2010weight patients is noninferior to prasugrel 10\u00a0mg in higher\u2010body\u2010weight patients: results from the FEATHER trial","volume":"60","author":"Erlinge","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl.","key":"10.1111\/jth.12219_bb0255","first-page":"675","article-title":"Prasugrel 5\u00a0mg in the very elderly is non\u2010inferior to prasugrel 10\u00a0mg in non\u2010elderly patients: the generations trial, a pharmacodynamic (PD) study in stable CAD patients","volume":"33","author":"Erlinge","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.12219_bb0260","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jacc.2010.02.072","article-title":"Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study","volume":"56","author":"Angiolillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0265","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.jacc.2012.02.042","article-title":"Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin\u2010treated patients with stable coronary disease: the RECOVERY trial","volume":"59","author":"Price","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0270","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","article-title":"Mortality benefit with prasugrel in the TRITON\u2010TIMI 38 coronary artery bypass grafting cohort: risk\u2010adjusted retrospective data analysis","volume":"60","author":"Smith","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/erc.09.172","article-title":"Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist","volume":"8","author":"Capodanno","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1111\/jth.12219_bb0280","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double\u2010blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0285","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0290","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCGENETICS.110.958561","article-title":"First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET\/OFFSET and RESPOND genotype studies","volume":"3","author":"Tantry","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1111\/jth.12219_bb0295","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0300","doi-asserted-by":"crossref","first-page":"d3527","DOI":"10.1136\/bmj.d3527","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non\u2010invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"342","author":"James","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/jth.12219_bb0305","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double\u2010blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/jth.12219_bb0310","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0315","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/CIRCULATIONAHA.112.124248","article-title":"Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study","volume":"127","author":"Kohli","year":"2013","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0320","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","article-title":"Ticagrelor versus clopidogrel in patients with ST\u2010elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis","volume":"122","author":"Steg","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0325","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.12219_bb0330","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0335","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ahj.2012.06.005","article-title":"Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes\u2010insights from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"164","author":"Cornel","year":"2012","journal-title":"Am Heart J"},{"key":"10.1111\/jth.12219_bb0340","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.964395","article-title":"Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"5","author":"Husted","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1111\/jth.12219_bb0345","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0350","article-title":"Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co\u2010administered with aspirin in healthy volunteers","author":"Teng","year":"2012","journal-title":"Platelets"},{"key":"10.1111\/jth.12219_bb0355","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.12219_bb0360","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","article-title":"Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET\/OFFSET study","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0365","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2010.11.056","volume":"57","author":"Scirica","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12219_bb0370","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/erc.09.101","article-title":"Cangrelor: a review on its mechanism of action and clinical development","volume":"7","author":"Ferreiro","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1111\/jth.12219_bb0375","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11239-012-0846-z","article-title":"Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation","volume":"35","author":"Ferreiro","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.12219_bb0380","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0385","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0390","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","article-title":"Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials","volume":"34","author":"Angiolillo","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.12219_bb0395","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","article-title":"Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect","volume":"121","author":"Steinhubl","year":"2008","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12219_bb0400","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1111\/jth.12219_bb0405","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0410","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"10.1111\/jth.12219_bb0415","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1681.2011.05616.x","article-title":"Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans","volume":"39","author":"Cushing","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1111\/jth.12219_bb0420","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/fca.10.67","article-title":"Elinogrel: pharmacological principles, preclinical and early phase clinical testing","volume":"6","author":"Ueno","year":"2010","journal-title":"Future Cardiol"},{"key":"10.1111\/jth.12219_bb0425","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","volume":"5","author":"Welsh","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1111\/jth.12219_bb0430","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCINTERVENTIONS.111.965608","volume":"5","author":"Angiolillo","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1111\/jth.12219_bb0435","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","article-title":"Platelet thrombin receptor antagonism and atherothrombosis","volume":"31","author":"Angiolillo","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.12219_bb0440","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin\u2010Receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0445","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12219_bb0450","doi-asserted-by":"crossref","DOI":"10.1161\/STROKEAHA.111.000433","article-title":"Efficacy and safety of vorapaxar in patients with prior ischemic stroke","author":"Morrow","year":"2013","journal-title":"Stroke"},{"key":"10.1111\/jth.12219_bb0455","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2\u00b0P\u2010TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"10.1111\/jth.12219_bb0460","unstructured":"Bonaca MP, Morrow DA, Braunwald E. Vorapaxar for secondary prevention in patients with peripheral artery disease: results from the peripheral artery disease cohort of the TRA 2\u00b0P\u2010TIMI 50 trial. American Heart Association Emerging Science Series Report. Available at http:\/\/my.americanheart.org\/professional\/Sessions\/AdditionalMeetings\/EmergingScienceSeries\/2012-Emerging-Science-Series%C2%97-June-20-2012_UCM_441183_Article.jsp"},{"key":"10.1111\/jth.12219_bb0465","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","article-title":"Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin\u2013Acute Coronary Syndromes Trial","volume":"123","author":"O'Donoghue","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0470","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","article-title":"Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin\u2013Coronary Artery Disease Trial","volume":"123","author":"Wiviott","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.12219_bb0475","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2012.04869.x","article-title":"Safety and efficacy of protease\u2010activated receptor\u20101 antagonists in patients with coronary artery disease: a meta\u2010analysis of randomized clinical trials","volume":"10","author":"Capodanno","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12219_bb0480","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/09537104.2012.704649","article-title":"Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease","volume":"23","author":"Rollini","year":"2012","journal-title":"Platelets"},{"key":"10.1111\/jth.12219_bb0485","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2174\/138945011797635876","article-title":"Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes","volume":"12","author":"Halim","year":"2011","journal-title":"Curr Drug Targets"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12219","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12219","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622051285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622051285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12219\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:07:49Z","timestamp":1761534469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622051285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":96,"alternative-id":["S1538783622051285"],"URL":"https:\/\/doi.org\/10.1111\/jth.12219","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet therapy: new pharmacological agents and changing paradigms","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}